Cycle-1: Next Generation Nkg2d-based Car T-cells In Aml/mds

2022 2:29
Synopsis
David Gilham, PhD, Celyad Oncology, Mont-Saint-Guibert, Belgium, describes the ongoing Phase 1 CYCLE-1 dose-escalation ...

You Might Also Like

NKG2D CAR-T cell therapy in AML/MDS 2:00
Nkg2d Car-t Cell Therapy In Aml/mds
2022
NKG2D-based CAR-T in R/R AML and MDS 2:21
Nkg2d-based Car-t In R/r Aml And Mds
2020
THINK trial: Phase I results for NKG2D CAR-T therapy in AML 4:03
Think Trial: Phase I Results For Nkg2d Car-t Therapy In Aml
2019
CAR T Cell Therapy in MDS/AML 1:31:25
Car T Cell Therapy In Mds/aml
2022
Insights into NKG2D-targeting CAR-T cells in R/R AML 1:30
Insights Into Nkg2d-targeting Car-t Cells In R/r Aml
2024
David Sallman, MD, offers details regarding the clinical investigation of CYAD-01 2:07
David Sallman, Md, Offers Details Regarding The Clinical Inv...
2021
Hurdles to CAR-T therapy for MDS & AML: T-cell fitness & lack of a uniform target antigen 1:16
Hurdles To Car-t Therapy For Mds & Aml: T-cell Fitness & Lac...
2024
NKG2D CARs for R/R AML and MDS 1:47
Nkg2d Cars For R/r Aml And Mds
2020
Dr. Park on Challenges With CAR T cells in AML 0:39
Dr. Park On Challenges With Car T Cells In Aml
2020
NKG2D-based CAR T-cells in solid tumors 1:46
Nkg2d-based Car T-cells In Solid Tumors
2026
Challenges With CAR T-Cell Therapies in AML 0:39
Challenges With Car T-cell Therapies In Aml
2020
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.